Smith & Nephew (SNN) Stock Forecast, Price & News

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Smith & Nephew in the last year. There are currently 2 sell ratings, 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" SNN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SNN, but not buy additional shares or sell existing shares.
View SNN analyst ratings or view top-rated stocks.

Smith & Nephew's stock was trading at $26.89 at the beginning of the year. Since then, SNN shares have increased by 11.8% and is now trading at $30.07.
View the best growth stocks for 2023 here.

Smith & Nephew saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 1,300,000 shares, an increase of 25.0% from the April 30th total of 1,040,000 shares. Based on an average trading volume of 931,300 shares, the days-to-cover ratio is currently 1.4 days. Currently, 0.3% of the company's stock are sold short.
View Smith & Nephew's Short Interest.

Smith & Nephew plc (NYSE:SNN) issued its earnings results on Monday, November, 17th. The medical equipment provider reported $0.98 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.39 by $0.59.

Smith & Nephew declared a semi-annual dividend on Monday, February 27th. Shareholders of record on Friday, March 31st will be paid a dividend of $0.462 per share on Wednesday, May 17th. This represents a yield of 2.6%. The ex-dividend date of this dividend is Thursday, March 30th. This is a positive change from the stock's previous semi-annual dividend of $0.29.
Read our dividend analysis for SNN.

ETFs with the largest weight of Smith & Nephew (NYSE:SNN) stock in their portfolio include ALPS Disruptive Technologies ETF (DTEC).SPDR S&P Kensho New Economies Composite ETF (KOMP).

Smith & Nephew (NYSE:SNN) pays an annual dividend of $0.90 per share and currently has a dividend yield of 3.01%.
Read our dividend analysis for SNN.

Based on aggregate information from My MarketBeat watchlists, some companies that other Smith & Nephew investors own include Smith & Nephew (SN), RPM International (RPM), Gilead Sciences (GILD), AbbVie (ABBV), Alibaba Group (BABA), Johnson & Johnson (JNJ), Pfizer (PFE), Abbott Laboratories (ABT), Alexion Pharmaceuticals (ALXN) and Amgen (AMGN).

Smith & Nephew trades on the New York Stock Exchange (NYSE) under the ticker symbol "SNN."

Smith & Nephew's stock is owned by a number of institutional and retail investors. Top institutional investors include Nuance Investments LLC (2.43%), Arrowstreet Capital Limited Partnership (0.59%), Scharf Investments LLC (0.51%), FMR LLC (0.46%), Bank of America Corp DE (0.23%) and Envestnet Asset Management Inc. (0.19%).

Shares of SNN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of SNN stock can currently be purchased for approximately $30.07.

Smith & Nephew (NYSE:SNN) has a market capitalization of $13.13 billion and generates $5.22 billion in revenue each year.

The company employs 19,012 workers across the globe.

Smith & Nephew's mailing address is BUILDING 5 CROXLEY PARK HATTERS LANE, WATFORD X0, WD18 8YE. The official website for the company is www.smith-nephew.com. The medical equipment provider can be reached via phone at 441923477100, via email at andrew.swift@smith-nephew.com, or via fax at 44-20-7930-3353.